Top Markets
Coin of the day
Oryzon Genomics S.A. Oryzon Genomics S.A.

Oryzon Genomics S.A.

ORY
株式のランク #16859
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in... Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
株価
$3.32
時価総額
$272.01M
変化(1日)
0.21%
変化(1年)
8.43%
ES
取引 Oryzon Genomics S.A. (ORY)

カテゴリー

Oryzon Genomics S.A.(ORY)の株価履歴
終値の最高値: $3.32 (2026-09-01)

終値の最安値: $4.05 (2015-12-01)
Oryzon Genomics S.A. の株価履歴(2015 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -3.02%
2025 127.05%
2024 -28.98%
2023 -7.72%
2022 -20.86%
2021 -17.47%
2020 14.60%
2019 14.88%
2018 -16.03%
2017 -30.04%
2016 21.22%
2015 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$548.15 36.70%
US
$1.03K 45.33%
NL
$153.87 536.09%
US
$122.21 -10.03%
AU
$757.71 8.20%
CH